During the first year of the Trump administration, signs of an anti-mRNA slant within the FDA and HHS became more and more ...

Nektar Therapeutics is basking in the honeyed glow of long-term phase 2 data for its immune asset rezpegaldesleukin in atopic ...

AstraZeneca is taking its oral GLP-1 drug into phase 3 on the back of a pair of midstage weight loss wins, despite remaining ...

German Merck has set up a new collaboration with U.K. medtech company Calla Lily Clinical Care to work on its next-generation ...

Evommune has aced its first major test as a public company, reporting phase 2a eczema data that caused its share price to jump 75% in premarket trading. The biotech, which went public late last year, ...

In October of last year, Kailera Therapeutics unveiled a whopping $600 mill | Kailera Therapeutics and its China partner ...

ILiAD Biotechnologies has closed an oversubscribed $115 million series B fundraise to support the company’s next-generation ...

OrsoBio’s experimental oral drug lowered fasting triglyceride levels at four weeks of treatment, hitting the primary efficacy goal in a midstage study of metabolic conditions. | OrsoBio’s experimental ...

There is a history of studying relaxin in cardiovascular settings—Novartis started a phase 3 heart failure trial of a recombinant relaxin-2 peptide in 2013—but preclinical evidence of the molecule’s ...

After facing a delayed decision deadline and a clinical hold, Regenxbio’s Hunter syndrome gene therapy has been rejected by ...

Bristol Myers Squibb is partnering up with Evinova’s AI clinical development platform across the Big Pharma company’s global portfolio in an effort to improve efficiency and cut costs.

The FDA has flagged J&J Medtech’s recall of its Cerepak detachable coils as Class I in the wake of one death and four serious ...